PSMA-targeted extracellular vesicles deliver siADAM9 to suppress tumor progression and enhance androgen-targeted therapy in prostate cancer
Extracellular Vesicles and Circulating Nucleic Acids · 02.11.2026 · 7 (4) · 1980-2005
DOI: 10.20517/evcna.2026.138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Extracellular Vesicles and Circulating Nucleic Acids, online erschienen am 02.11.2026. Verfasst von Mafewu Olga Raboshakga und 5 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Aim
The progression of prostate cancer to metastatic and castration-resistant disease remains a major therapeutic challenge, and a disintegrin and metalloproteinase 9 (ADAM9) has emerged as a key regulator of tumor progression and adaptive androgen receptor signaling. We aimed to develop a prostate-specific membrane antigen (PSMA)-targeted extracellular vesicle (EV) platform for selective delivery of small interfering RNA (siRNA) against ADAM9 (siADAM9) and evaluate its therapeutic potential in prostate cancer.
Methods
Mesenchymal stem cell (MSC)-derived EVs were engineered to display a PSMA-targeting single-chain variable fragment (PSMA-scFv). Targeting specificity and cellular uptake were evaluated in PSMA-expressing and PSMA-negative prostate cancer cells. Functional effects of EV-mediated siADAM9 delivery were assessed by proliferation, migration, and sphere formation assays in hormone-sensitive (LNCaP) and castration-resistant (CWR22Rv1) prostate cancer models. Gene and protein expression were analyzed by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and immunoblotting. Therapeutic efficacy was further evaluated in combination with androgen deprivation therapy and abiraterone.
Results
PSMA-scFv functionalization enabled selective EV binding and uptake in a PSMA-dependent manner. Through this targeting strategy, EV-mediated siADAM9 delivery effectively suppressed ADAM9 expression and inhibited malignant phenotypes, including proliferation, migration, and tumor sphere formation, while reversing epithelial-mesenchymal transition- and stemness-associated molecular programs. Moreover, EVs loaded with siADAM9 (EV-siADAM9) enhanced the efficacy of androgen-targeted therapy in both hormone-sensitive and castration-resistant prostate cancer models. These effects were associated with disruption of ADAM9 downstream signaling, including aldo-keto reductase family 1 member C3 (AKR1C3)-mediated androgen biosynthesis and cell-cycle regulation.
Conclusion
These findings provide in vitro proof-of-concept that PSMA-targeted EVs preferentially deliver siADAM9, suppress tumor-promoting programs, and enhance androgen-targeted therapy, supporting further preclinical evaluation of this platform.
Zitieren
APA
Raboshakga, M. O., Do, A. D., Shiau, G. H. M., Shigemura, K., Hsieh, C., & Sung, S. (2026). PSMA-targeted extracellular vesicles deliver siADAM9 to suppress tumor progression and enhance androgen-targeted therapy in prostate cancer. Extracellular Vesicles and Circulating Nucleic Acids, 7(4), 1980-2005. https://doi.org/10.20517/evcna.2026.138
Vancouver
Raboshakga MO, Do AD, Shiau GHM, Shigemura K, Hsieh C, Sung S. PSMA-targeted extracellular vesicles deliver siADAM9 to suppress tumor progression and enhance androgen-targeted therapy in prostate cancer. Extracellular Vesicles and Circulating Nucleic Acids. 2026;7(4):1980-2005. doi:10.20517/evcna.2026.138
BibTeX
@article{Raboshakga2026,
author = {Raboshakga, Mafewu Olga and Do, Anh Duy and Shiau, Gwo Harn Max and Shigemura, Katsumi and Hsieh, Chia-Ling and Sung, Shian-Ying},
title = {PSMA-targeted extracellular vesicles deliver siADAM9 to suppress tumor progression and enhance androgen-targeted therapy in prostate cancer},
journal = {Extracellular Vesicles and Circulating Nucleic Acids},
year = {2026},
volume = {7},
number = {4},
pages = {1980--2005},
doi = {10.20517/evcna.2026.138}
}
EUVIMED